Details of the HIV-infected subjects included in the study, the time point(s) studied in each person, and the response analyzed at each time point
| Patient no. . | Early treatment?* (persisting viral load established if untreated) . | Acute time point(s) studied . | Chronic time point(s) studied . | ||||
|---|---|---|---|---|---|---|---|
| DFOSx . | Viral load, HIV RNA copies/mL . | Response analyzed† . | DFOSx . | Viral load, HIV RNA copies/mL . | Response analyzed† . | ||
| MM1 | No early ART (96 285) | 1839 | 43 100 | B8-FLK | |||
| 2702 | 22 200 | B8-FLK | |||||
| MM3 | On ART from 30-1138 DFOSx | 1265 | 2400 | A2-SLY | |||
| 2527 | 15 300 | A2-SLY | |||||
| MM5 | On ART from 29-842 DFOSx | 1383 | 2100 | A2-SLY | |||
| 1832 | 2300 | A2-SLY | |||||
| 2351 | 7800 | A2-SLY | |||||
| MM9 | No early ART (33 400) | 602 | 143 000 | B8-EIY | |||
| 945 | 217 600 | B8-EIY | |||||
| MM12 | No early ART (40 738) | 487 | 116 000 | A3-QVP | |||
| MM14 | No early ART (35 300) | 47 | 2 162 300 | B8-FLK | 1394 | 19 700 | B8-FLK |
| MM15 | No early ART (66 367) | 720 | 27 500 | A2-SLY | |||
| MM24 | No early ART (108 125) | 23 | 277 700 | B8-EIY | 1322 | ND | B8-EIY |
| MM27 | No early ART (32 517) | 32 | 108 200 | A3-RLR | 585 | 26 400 | A3-RLR |
| 39 | 67 200 | A3-RLR | 756 | 12 400 | A3-RLR | ||
| 1210 | 331 600 | A3-RLR | |||||
| MM30 | On ART from 47-387 DFOSx | 22 | 245 000 | A2-RIR | 1038 | 231 100 | A2-RIR |
| 1449 | 52 800 | A2-RIR | |||||
| MM34 | No early ART (9638) | 607 | 9500 | A24-RYP | |||
| 1310 | 40 700 | A24-RYP | |||||
| MM38 | On ART from 115-414 DFOSx | 499 | 313 900 | B8-FLK | |||
| MM40 | No early ART (9333) | 25 | 1000 | A24-RYPF | 747 | 89 000 | B7-IPR |
| 32 | 2100 | A24-RYPF | 1166 | 140 000 | B7-IPR | ||
| MM47 | No early ART (13 804) | 35 | ND | A24-RYPF | |||
| MM48 | No early ART (4265) | 29 | 94 700 | B27-KRW | 640 | < 50 | B27-KRW |
| 50 | 4200 | B27-KRW | |||||
| MM50 | No early ART (63 096) | 39 | 111 900 | A3-RLR | |||
| 46 | 86 100 | A3-RLR | |||||
| MM52 | On ART from 31-143 DFOSx | 475 | 7900 | A1-GSE | |||
| MM53 | On ART from 33-141 DFOSx | 344 | 41 000 | B27-KRW | |||
| MM54 | On ART from 49-156 DFOSx | 37 | 27 000 | A3-RLR | 380 | 4700 | A3-RLR |
| 587 | 35 000 | A3-RLR | |||||
| MM56 | No early ART (1023) | 25 | 20 000 | B57-TST | 187 | 1300 | B57-TST |
| 376 | 4000 | A2-LVW | |||||
| MM59 | On ART from 45-392 DFOSx | 38 | 120 000 | A3-QIY | |||
| Patient no. . | Early treatment?* (persisting viral load established if untreated) . | Acute time point(s) studied . | Chronic time point(s) studied . | ||||
|---|---|---|---|---|---|---|---|
| DFOSx . | Viral load, HIV RNA copies/mL . | Response analyzed† . | DFOSx . | Viral load, HIV RNA copies/mL . | Response analyzed† . | ||
| MM1 | No early ART (96 285) | 1839 | 43 100 | B8-FLK | |||
| 2702 | 22 200 | B8-FLK | |||||
| MM3 | On ART from 30-1138 DFOSx | 1265 | 2400 | A2-SLY | |||
| 2527 | 15 300 | A2-SLY | |||||
| MM5 | On ART from 29-842 DFOSx | 1383 | 2100 | A2-SLY | |||
| 1832 | 2300 | A2-SLY | |||||
| 2351 | 7800 | A2-SLY | |||||
| MM9 | No early ART (33 400) | 602 | 143 000 | B8-EIY | |||
| 945 | 217 600 | B8-EIY | |||||
| MM12 | No early ART (40 738) | 487 | 116 000 | A3-QVP | |||
| MM14 | No early ART (35 300) | 47 | 2 162 300 | B8-FLK | 1394 | 19 700 | B8-FLK |
| MM15 | No early ART (66 367) | 720 | 27 500 | A2-SLY | |||
| MM24 | No early ART (108 125) | 23 | 277 700 | B8-EIY | 1322 | ND | B8-EIY |
| MM27 | No early ART (32 517) | 32 | 108 200 | A3-RLR | 585 | 26 400 | A3-RLR |
| 39 | 67 200 | A3-RLR | 756 | 12 400 | A3-RLR | ||
| 1210 | 331 600 | A3-RLR | |||||
| MM30 | On ART from 47-387 DFOSx | 22 | 245 000 | A2-RIR | 1038 | 231 100 | A2-RIR |
| 1449 | 52 800 | A2-RIR | |||||
| MM34 | No early ART (9638) | 607 | 9500 | A24-RYP | |||
| 1310 | 40 700 | A24-RYP | |||||
| MM38 | On ART from 115-414 DFOSx | 499 | 313 900 | B8-FLK | |||
| MM40 | No early ART (9333) | 25 | 1000 | A24-RYPF | 747 | 89 000 | B7-IPR |
| 32 | 2100 | A24-RYPF | 1166 | 140 000 | B7-IPR | ||
| MM47 | No early ART (13 804) | 35 | ND | A24-RYPF | |||
| MM48 | No early ART (4265) | 29 | 94 700 | B27-KRW | 640 | < 50 | B27-KRW |
| 50 | 4200 | B27-KRW | |||||
| MM50 | No early ART (63 096) | 39 | 111 900 | A3-RLR | |||
| 46 | 86 100 | A3-RLR | |||||
| MM52 | On ART from 31-143 DFOSx | 475 | 7900 | A1-GSE | |||
| MM53 | On ART from 33-141 DFOSx | 344 | 41 000 | B27-KRW | |||
| MM54 | On ART from 49-156 DFOSx | 37 | 27 000 | A3-RLR | 380 | 4700 | A3-RLR |
| 587 | 35 000 | A3-RLR | |||||
| MM56 | No early ART (1023) | 25 | 20 000 | B57-TST | 187 | 1300 | B57-TST |
| 376 | 4000 | A2-LVW | |||||
| MM59 | On ART from 45-392 DFOSx | 38 | 120 000 | A3-QIY | |||
When responses were analyzed none of the patients studied was receiving therapy for at least 2 years.
DFOSx indicates duration of infection (measured in days after the onset of symptoms of the acute retroviral syndrome); and ND, not determined.
Some subjects studied at the chronic stage elected to receive antiretroviral therapy (ART) starting shortly after diagnosis or in early infection. The persisting viral load was established after control of the acute viral burst (calculated as described by Fellay et al36 in patients that did not receive therapy during the acute infection).
HIV epitope-specific CD8 T cells were identified by tetramer staining. The epitope-specific T-cell population analyzed at each time point is designated by the restricting HLA allele, followed by the first 3 or 4 residues of the epitope sequence.